Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.
A two-pronged approach combining virus and immune cells tackled glioblastoma from multiple angles in early laboratory studies.
Researchers developed a combination therapy using an oncolytic virus that delivers target antigens alongside bispecific CAR-T cells to attack glioblastoma from multiple angles. This dual approach showed promising tumor killing in laboratory models of an otherwise difficult-to-treat brain cancer.
What the study was
- Study design
- Preclinical (in vitro and in vivo models)
- Population
- Glioblastoma preclinical models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nature Communications
Why it surfaced
Novel multimodal oncolytic virus + bispecific CAR-T platform for GBM from Maus/Fong labs in Nat Commun. High unmet need but preclinical.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.